Home
IMPACT PH Lecture Series
Education
PAH.tv Network
Slidesets and Resources
You are here :
PAH.tv Network
Login
|
Register
Please select a video from the list below.
Macitentan in PH Due to LV Dysfunction: MELODY-1
PH is a common coincidence with heart failure. Recent guidelines identified 2 types of Group 2 PH, isolated post-capillary PH and combined pre and post capillary PH (CpcPH), which in heart failure patients are associated with elevated endothelin-1 levels. The effects of macitentan on fluid retention are particularly important and may serve to alter physicians’ perceptions for use of this medication in Group 2 patients. Dr. Lewis Rubin discusses the design and results of the MELODY-1 trial, macitentan in PH due to LV dysfunction.
Slide set - Macitentan in Pulmonary Hypertension Due To Left Ventricular Dysfunction: MELODY-1
Recent Video
|
Most Viewed
Specialties :
<All Specialties>
Allied Health
Clinical Insights
Clinical Trials
Lecturer Bios
News
PAH
Search :
Hemodynamics Markers of PH and Outcomes in Heart Failure With HFpEF
Views - 65
Clinical Worsening in Higher Risk Patients
Views - 102
Approach to Treatment in Inoperable CTEPH
Views - 152
Transitioning Patients Between PH Therapies
Views - 285
Plasma BNP Predicts 5-Year Overall Survival in PAH
Views - 309
Are Direct Oral Anticoagulants Appropriate for PAH?
Views - 376
Options When Prostacyclin Side Effects are Unmanageable
Views - 394
SIOVAC: Sildenafil for PH after Mitral Valve Surgery
Views - 2165
Macitentan in PH Due to LV Dysfunction: MELODY-1
Views - 475
Is Up-Front Triple Combination Therapy in PAH "A Thing"?
Views - 411
New Therapies for CTEPH
Views - 336
New Therapies for Group 1 PAH
Views - 408
How to Screen for PAH in Scleroderma-Spectrum Disorders
Views - 449
PAH-Related Morbidity Is Prognostic for Mortality
Views - 753
Pulmonary Hypertension Association Update
Views - 191
Getting Aggressive in PAH: Setting Goals and Escalating Care
Views - 544
Strategies for Transitioning Therapy in PAH
Views - 56
Palliative Care in PAH: Best Practice or Too Little, Too Late
Views - 70
Newer Medications and How To Use Them
Views - 77
Clinical Research Year in Review
Views - 58
Advances in Imaging for Lung Vasculature
Views - 64
Bleeding and Thrombosis After PTE
Views - 39
Serum CXC-Chemokine Ligand 10 is Associated with Severity of Chronic Thromboembolic Pulmonary Hypertension
Views - 28
NEDD9 is Upregulated By Hypoxia in Human Pulmonary Artery Endothelial Cells Selectively and Modulates Platelet-Endothelial Adhesion
Views - 36
Management of Severe Right Heart Failure in PTE Patients
Views - 35
The Imposters: What (almost) Everyone Thinks is CTEPH
Views - 31
Absence of the Factor V Leiden Mutation and Genetic Risk For CTEPH
Views - 50
Pulmonary Embolism, CTED and CTEPH: Connecting the Dots
Views - 47
Evaluation of CTEPH: VQ Scans and Planar Angiography
Views - 41
Patients with CTEPH Should Be Started on PAH Therapy Prior to PTE
Views - 59
An Overview of PH Directed Medical Therapy in CTEPH
Views - 47
CTED and the Value of Exercise Testing
Views - 30
Future Directions in CTEPH
Views - 49
Balloon Pulmonary Angioplasty for CTEPH: Patient Selection
Views - 56
CTEPH Patients Should NOT Be Started on PH Medical Therapy Before PTE
Views - 19
Mechanism of Lumen Enlargement and Pulmonary Injury In Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension
Views - 18
Distal Pulmonary Thromboendarterecomy: Is It Worth It?
Views - 17
Medical Decision in BPA
Views - 33
The Pursuit of Minimally Invasive Pulmonary Thromboendarterectomy
Views - 13
The Dilemma of CTEPH
Views - 92
Challenges of PAH in Heart Failure With Preserved Ejection Fraction
Views - 1819
Weighing Strategic Treatment Options in the Current Era of PAH Medicine
Views - 1183
Expanding the Therapeutic Range of Current PAH Medications: What Next?
Views - 118
Selexipag for the Treatment of Connective Tissue Disease-Associated PAH
Views - 295
RESPITE Study Results
Views - 1174
Assessing Risk in PAH Patients
Views - 917
When to Add or Switch Therapy
Views - 388
RESPITE: Evidence to Support a Switch Approach?
Views - 545
Switching from PDE-5 to sGC Stimulator
Views - 257
What is Tolerance to Therapy on PDE-5 or PGI-2?
Views - 199
What are the Choices When Escalating Therapy?
Views - 907
Parameters for Treatment Success
Views - 797
When Should Patients be Evaluated for Efficacy?
Views - 311
General Goals of Therapy for Patient on Monotherapy
Views - 1620
Early Combination Therapy: Applying Aggressive Goals
Views - 163
Preventing Hospitalization in PAH Through Aggressive Early Therapy
Views - 195
Future Directions in PAH Therapy and Clinical Research
Views - 613
Quality of Life Issues in the Treatment of PAH
Views - 1107
What Are the Risks to Combination Therapy?
Views - 83
Neurohormone in the Pathobiology of PH: Beta-blockers
Views - 65
Palliative Care in Pulmonary Arterial Hypertension
Views - 162
Oral Prostanoids for the Mgmt of PH: The Holy Grail or Beraprost Revisited?
Views - 370
Neurohormone in the pathobiology of PH: RAAS
Views - 46
Case Presentation: Palliative Care in PAH
Views - 23
Mitral Valve Disease and the Development of Pulmonary Arteriopathy
Views - 150
Vascular and Endothelial Biomarkers in PAH
Views - 54
Case of Atrial Septal Defect Associated with PH
Views - 1661
WHO Group II PH Due to Heart Failure w/Preserved Ejection Fraction
Views - 829
Case of a 58 Year Old with Scleroderma
Views - 492
Understanding the Diagnosis and Treatment of PAH
Views - 404
20 Years of Prostanoids: Spanning the Continuum of Care in PAH
Views - 720
Group 1 and Beyond: Case Studies in PH
Views - 230
Insights from Fetal Imaging
Views - 115
Pathophysiology of PH in the ICU
Views - 112
ICU Management of PH
Views - 157
Privacy
|
Terms Of Use
|
Contact Us
|
Copyright 2019 by PAH.tv
|
About PAH.tv